25 XP   0   0   10

Endonovo Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Endonovo together

PenkeI guess you are interested in Endonovo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Endonovo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Endonovo Therapeutics Inc

I send you an email if I find something interesting about Endonovo Therapeutics Inc.

Quick analysis of Endonovo (30 sec.)










What can you expect buying and holding a share of Endonovo? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.04
Expected worth in 1 year
$0.01
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$0.05
Return On Investment
4,034.5%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.001 - $0.0036
How sure are you?
50%

1. Valuation of Endonovo (5 min.)




Live pricePrice per Share (EOD)

$0.00

Intrinsic Value Per Share

$-0.03 - $0.02

Total Value Per Share

$-0.07 - $-0.02

2. Growth of Endonovo (5 min.)




Is Endonovo growing?

Current yearPrevious yearGrowGrow %
How rich?-$24.8m-$25.7m$2.2m9.6%

How much money is Endonovo making?

Current yearPrevious yearGrowGrow %
Making money-$253.8k-$6.7m$6.5m2,565.9%
Net Profit Margin-20,276.8%-131,509.6%--

How much money comes from the company's main activities?

3. Financial Health of Endonovo (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#955 / 995

Most Revenue
#738 / 995

Most Profit
#185 / 995

Most Efficient
#949 / 995

What can you expect buying and holding a share of Endonovo? (5 min.)

Welcome investor! Endonovo's management wants to use your money to grow the business. In return you get a share of Endonovo.

What can you expect buying and holding a share of Endonovo?

First you should know what it really means to hold a share of Endonovo. And how you can make/lose money.

Speculation

The Price per Share of Endonovo is $0.0013. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Endonovo.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Endonovo, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.04. Based on the TTM, the Book Value Change Per Share is $0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Endonovo.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-87.3%0.00-122.9%-0.02-1,443.8%-0.01-542.5%-0.01-448.2%
Usd Book Value Change Per Share0.032,256.9%0.011,008.6%-0.01-903.0%0.00-27.1%0.00-53.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.032,256.9%0.011,008.6%-0.01-903.0%0.00-27.1%0.00-53.5%
Usd Price Per Share0.00-0.01-0.01-0.13-0.33-
Price to Earnings Ratio-0.68--0.06--0.41--2.44--34.06-
Price-to-Total Gains Ratio0.11--0.65--2.41--16.16--771.94-
Price to Book Ratio-0.08--0.32--0.17--2.32--19.05-
Price-to-Total Gains Ratio0.11--0.65--2.41--16.16--771.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0013
Number of shares769230
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.00
Usd Total Gains Per Share0.010.00
Gains per Quarter (769230 shares)10,086.18-271.17
Gains per Year (769230 shares)40,344.73-1,084.69
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1040345403350-1085-1095
2080689806800-2169-2180
301210341210250-3254-3265
401613791613700-4339-4350
502017242017150-5423-5435
602420682420600-6508-6520
702824132824050-7593-7605
803227583227500-8678-8690
903631033630950-9762-9775
1004034474034400-10847-10860

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.033.00.017.5%7.045.00.013.5%
Book Value Change Per Share2.02.00.050.0%3.07.02.025.0%4.012.04.020.0%9.024.07.022.5%10.032.010.019.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.052.00.0%
Total Gains per Share2.02.00.050.0%3.07.02.025.0%4.012.04.020.0%9.024.07.022.5%10.032.010.019.2%

Fundamentals of Endonovo

About Endonovo Therapeutics Inc

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

Fundamental data was last updated by Penke on 2024-05-16 07:34:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Endonovo Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Endonovo earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • A Net Profit Margin of -8,463.1% means that $-84.63 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Endonovo Therapeutics Inc:

  • The MRQ is -8,463.1%. The company is making a huge loss. -2
  • The TTM is -20,276.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8,463.1%TTM-20,276.8%+11,813.7%
TTM-20,276.8%YOY-131,509.6%+111,232.9%
TTM-20,276.8%5Y41,065.2%-61,341.9%
5Y41,065.2%10Y28,722.6%+12,342.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,463.1%-177.0%-8,286.1%
TTM-20,276.8%-223.7%-20,053.1%
YOY-131,509.6%-256.7%-131,252.9%
5Y41,065.2%-431.4%+41,496.6%
10Y28,722.6%-551.3%+29,273.9%
1.1.2. Return on Assets

Shows how efficient Endonovo is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • -148.9% Return on Assets means that Endonovo generated $-1.49 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Endonovo Therapeutics Inc:

  • The MRQ is -148.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -72.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-148.9%TTM-72.5%-76.4%
TTM-72.5%YOY-514.0%+441.5%
TTM-72.5%5Y-153.2%+80.7%
5Y-153.2%10Y-515.5%+362.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-148.9%-11.9%-137.0%
TTM-72.5%-11.7%-60.8%
YOY-514.0%-10.8%-503.2%
5Y-153.2%-13.0%-140.2%
10Y-515.5%-14.2%-501.3%
1.1.3. Return on Equity

Shows how efficient Endonovo is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • 0.0% Return on Equity means Endonovo generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.1%+15.1%
TTM--14.7%+14.7%
YOY--13.3%+13.3%
5Y--17.6%+17.6%
10Y--19.1%+19.1%

1.2. Operating Efficiency of Endonovo Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Endonovo is operating .

  • Measures how much profit Endonovo makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • An Operating Margin of -4,772.6% means the company generated $-47.73  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Endonovo Therapeutics Inc:

  • The MRQ is -4,772.6%. The company is operating very inefficient. -2
  • The TTM is -13,011.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-4,772.6%TTM-13,011.7%+8,239.1%
TTM-13,011.7%YOY-70,514.7%+57,503.0%
TTM-13,011.7%5Y-30,311.5%+17,299.7%
5Y-30,311.5%10Y-13,579.1%-16,732.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,772.6%-348.2%-4,424.4%
TTM-13,011.7%-232.7%-12,779.0%
YOY-70,514.7%-266.9%-70,247.8%
5Y-30,311.5%-412.2%-29,899.3%
10Y-13,579.1%-516.7%-13,062.4%
1.2.2. Operating Ratio

Measures how efficient Endonovo is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 48.73 means that the operating costs are $48.73 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 48.725. The company is inefficient in keeping operating costs low. -1
  • The TTM is 130.696. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ48.725TTM130.696-81.971
TTM130.696YOY706.157-575.460
TTM130.6965Y303.536-172.840
5Y303.53610Y98.779+204.757
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ48.7253.097+45.628
TTM130.6963.332+127.364
YOY706.1573.564+702.593
5Y303.5365.224+298.312
10Y98.7796.637+92.142

1.3. Liquidity of Endonovo Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Endonovo is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.00 means the company has $0.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.001. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.002. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.001TTM0.002-0.001
TTM0.002YOY0.001+0.001
TTM0.0025Y0.003-0.002
5Y0.00310Y0.010-0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0013.798-3.797
TTM0.0024.146-4.144
YOY0.0015.212-5.211
5Y0.0036.093-6.090
10Y0.0106.441-6.431
1.3.2. Quick Ratio

Measures if Endonovo is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.000. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.000. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.000TTM0.0000.000
TTM0.000YOY0.000+0.000
TTM0.0005Y0.002-0.002
5Y0.00210Y0.005-0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0003.165-3.165
TTM0.0003.776-3.776
YOY0.0005.140-5.140
5Y0.0025.839-5.837
10Y0.0056.367-6.362

1.4. Solvency of Endonovo Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Endonovo assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Endonovo to Biotechnology industry mean.
  • A Debt to Asset Ratio of 53.07 means that Endonovo assets are financed with 5,307.0% credit (debt) and the remaining percentage (100% - 5,307.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 53.070. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 35.945. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ53.070TTM35.945+17.125
TTM35.945YOY19.939+16.006
TTM35.9455Y15.423+20.521
5Y15.42310Y32.489-17.065
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ53.0700.340+52.730
TTM35.9450.341+35.604
YOY19.9390.279+19.660
5Y15.4230.366+15.057
10Y32.4890.380+32.109
1.4.2. Debt to Equity Ratio

Measures if Endonovo is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.388-0.388
TTM-0.415-0.415
YOY-0.356-0.356
5Y-0.443-0.443
10Y-0.469-0.469

2. Market Valuation of Endonovo Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Endonovo generates.

  • Above 15 is considered overpriced but always compare Endonovo to the Biotechnology industry mean.
  • A PE ratio of -0.68 means the investor is paying $-0.68 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Endonovo Therapeutics Inc:

  • The EOD is -0.287. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.683. Based on the earnings, the company is expensive. -2
  • The TTM is -0.055. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.287MRQ-0.683+0.397
MRQ-0.683TTM-0.055-0.628
TTM-0.055YOY-0.411+0.356
TTM-0.0555Y-2.443+2.388
5Y-2.44310Y-34.060+31.617
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.287-2.289+2.002
MRQ-0.683-2.558+1.875
TTM-0.055-2.723+2.668
YOY-0.411-3.900+3.489
5Y-2.443-6.368+3.925
10Y-34.060-6.544-27.516
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Endonovo Therapeutics Inc:

  • The EOD is -92.181. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -219.816. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -66.184. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-92.181MRQ-219.816+127.635
MRQ-219.816TTM-66.184-153.633
TTM-66.184YOY-5.597-60.587
TTM-66.1845Y-54.389-11.794
5Y-54.38910Y-117.423+63.033
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-92.181-3.247-88.934
MRQ-219.816-3.308-216.508
TTM-66.184-3.522-62.662
YOY-5.597-5.154-0.443
5Y-54.389-8.005-46.384
10Y-117.423-8.608-108.815
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Endonovo is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.08 means the investor is paying $-0.08 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Endonovo Therapeutics Inc:

  • The EOD is -0.033. Based on the equity, the company is expensive. -2
  • The MRQ is -0.078. Based on the equity, the company is expensive. -2
  • The TTM is -0.320. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.033MRQ-0.078+0.045
MRQ-0.078TTM-0.320+0.241
TTM-0.320YOY-0.168-0.152
TTM-0.3205Y-2.318+1.998
5Y-2.31810Y-19.051+16.733
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0331.996-2.029
MRQ-0.0782.027-2.105
TTM-0.3202.073-2.393
YOY-0.1682.696-2.864
5Y-2.3183.727-6.045
10Y-19.0514.109-23.160
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Endonovo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0290.013+124%-0.012+140%0.000+101%-0.001+102%
Book Value Per Share---0.040-0.048+20%-0.074+86%-0.052+31%-0.038-5%
Current Ratio--0.0010.002-54%0.001+19%0.003-79%0.010-93%
Debt To Asset Ratio--53.07035.945+48%19.939+166%15.423+244%32.489+63%
Debt To Equity Ratio----0%-0%-0%-0%
Dividend Per Share----0%-0%-0%-0%
Eps---0.001-0.002+41%-0.019+1555%-0.007+522%-0.006+414%
Free Cash Flow Per Share--0.0000.000-101%-0.001+15759%-0.001+17808%-0.001+31253%
Free Cash Flow To Equity Per Share--0.0000.000+615%0.000+2174%0.000+58%0.001-100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.019--------
Intrinsic Value_10Y_min---0.031--------
Intrinsic Value_1Y_max---0.001--------
Intrinsic Value_1Y_min---0.004--------
Intrinsic Value_3Y_max---0.001--------
Intrinsic Value_3Y_min---0.012--------
Intrinsic Value_5Y_max--0.002--------
Intrinsic Value_5Y_min---0.018--------
Market Cap454212.179-327%1938777.8327241662.944-73%4446038.446-56%44678850.229-96%114465010.361-98%
Net Profit Margin---84.631-202.768+140%-1315.096+1454%410.652-121%287.226-129%
Operating Margin---47.726-130.117+173%-705.147+1377%-303.115+535%-135.791+185%
Operating Ratio--48.725130.696-63%706.157-93%303.536-84%98.779-51%
Pb Ratio-0.033+58%-0.078-0.320+309%-0.168+114%-2.318+2865%-19.051+24270%
Pe Ratio-0.287+58%-0.683-0.055-92%-0.411-40%-2.443+258%-34.060+4885%
Price Per Share0.001-138%0.0030.010-68%0.013-76%0.126-98%0.327-99%
Price To Free Cash Flow Ratio-92.181+58%-219.816-66.184-70%-5.597-97%-54.389-75%-117.423-47%
Price To Total Gains Ratio0.044-138%0.106-0.653+718%-2.410+2381%-16.157+15392%-771.935+730693%
Quick Ratio--0.0000.000-98%0.000-97%0.002-100%0.005-100%
Return On Assets---1.489-0.725-51%-5.140+245%-1.532+3%-5.155+246%
Return On Equity----0%-0%-0%-0%
Total Gains Per Share--0.0290.013+124%-0.012+140%0.000+101%-0.001+102%
Usd Book Value---24800747.000-23517252.250-5%-25781662.750+4%-19572981.600-21%-13912606.200-44%
Usd Book Value Change Per Share--0.0290.013+124%-0.012+140%0.000+101%-0.001+102%
Usd Book Value Per Share---0.040-0.048+20%-0.074+86%-0.052+31%-0.038-5%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.001-0.002+41%-0.019+1555%-0.007+522%-0.006+414%
Usd Free Cash Flow---2205.00073205.250-103%-195356.250+8760%-226794.400+10185%-389323.000+17556%
Usd Free Cash Flow Per Share--0.0000.000-101%-0.001+15759%-0.001+17808%-0.001+31253%
Usd Free Cash Flow To Equity Per Share--0.0000.000+615%0.000+2174%0.000+58%0.001-100%
Usd Market Cap454212.179-327%1938777.8327241662.944-73%4446038.446-56%44678850.229-96%114465010.361-98%
Usd Price Per Share0.001-138%0.0030.010-68%0.013-76%0.126-98%0.327-99%
Usd Profit---709376.000-253821.000-64%-6766578.500+854%-2672320.450+277%-1809573.225+155%
Usd Revenue--8382.00015271.000-45%63634.000-87%43779.650-81%51556.975-84%
Usd Total Gains Per Share--0.0290.013+124%-0.012+140%0.000+101%-0.001+102%
 EOD+1 -7MRQTTM+17 -14YOY+24 -75Y+20 -1110Y+16 -15

3.2. Fundamental Score

Let's check the fundamental score of Endonovo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.287
Price to Book Ratio (EOD)Between0-1-0.033
Net Profit Margin (MRQ)Greater than0-84.631
Operating Margin (MRQ)Greater than0-47.726
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.001
Debt to Asset Ratio (MRQ)Less than153.070
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.489
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Endonovo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.103
Ma 20Greater thanMa 500.002
Ma 50Greater thanMa 1000.002
Ma 100Greater thanMa 2000.004
OpenGreater thanClose0.001
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets476
Total Liabilities25,277
Total Stockholder Equity-24,801
 As reported
Total Liabilities 25,277
Total Stockholder Equity+ -24,801
Total Assets = 476

Assets

Total Assets476
Total Current Assets18
Long-term Assets458
Total Current Assets
Cash And Cash Equivalents 0
Other Current Assets 18
Total Current Assets  (as reported)18
Total Current Assets  (calculated)18
+/-0
Long-term Assets
Long-term Assets Other 457
Long-term Assets  (as reported)458
Long-term Assets  (calculated)457
+/- 2

Liabilities & Shareholders' Equity

Total Current Liabilities25,197
Long-term Liabilities80
Total Stockholder Equity-24,801
Total Current Liabilities
Short-term Debt 7,058
Accounts payable 1,097
Other Current Liabilities 17,042
Total Current Liabilities  (as reported)25,197
Total Current Liabilities  (calculated)25,197
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)80
Long-term Liabilities  (calculated)0
+/- 80
Total Stockholder Equity
Common Stock34
Retained Earnings -68,943
Accumulated Other Comprehensive Income -34
Other Stockholders Equity 44,143
Total Stockholder Equity (as reported)-24,801
Total Stockholder Equity (calculated)-24,801
+/- 0
Other
Cash and Short Term Investments 0
Common Stock Shares Outstanding 625,412
Liabilities and Stockholders Equity 476
Net Debt 7,058
Net Working Capital -25,179
Short Long Term Debt Total 7,058



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302010-12-31
> Total Assets 
170
100
990
990
988
969
78
78
74
64
74
74
196
99
46
46
54
62
76
76
102
264
319
319
203
160
4,612
4,612
4,284
4,711
4,242
4,242
4,123
3,414
3,275
3,275
2,896
2,732
2,607
2,607
2,274
2,137
2,007
2,007
1,595
1,451
1,281
1,281
1,015
816
640
476
4766408161,0151,2811,2811,4511,5952,0072,0072,1372,2742,6072,6072,7322,8963,2753,2753,4144,1234,2424,2424,7114,2844,6124,61216020331931926410276766254464699196747464747878969988990990100170
   > Total Current Assets 
160
100
10
10
26
19
1
1
2
1
3
3
152
58
3
3
18
30
44
44
79
245
303
303
195
155
111
111
99
689
382
382
586
39
63
63
10
9
46
46
39
63
95
95
6
24
16
16
73
36
20
18
182036731616246959563394646910636339586382382689991111111551953033032457944443018335815233121119261010100160
       Cash And Cash Equivalents 
30
100
10
10
11
3
1
1
2
1
3
3
145
51
1
1
18
27
41
41
79
95
56
56
24
64
90
90
68
665
379
379
548
5
19
19
5
3
13
13
9
6
86
86
0
23
0
0
33
0
2
0
020330023086866913133519195548379379665689090642456569579414127181151145331211311101010030
       Net Receivables 
130
0
0
1
1
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
10
3
3
3
8
11
23
23
1
1
1
1
9
7
1
1
1
1
0
3
0
0
0
0
0000301111791111232311833310700000000000000000000021100130
       Other Current Assets 
0
0
0
0
14
14
0
0
0
0
0
0
7
7
2
2
0
3
3
3
0
150
247
247
171
91
21
21
21
21
0
0
0
0
0
21
3
3
0
32
21
50
0
8
5
0
16
16
40
36
18
18
18183640161605805021320332100000212121219117124724715003330227700000014140000
   > Long-term Assets 
10
0
980
980
962
949
77
77
72
63
70
70
44
41
43
43
35
32
32
32
24
20
0
16
8
5
0
4,501
4,185
4,023
0
3,860
3,537
3,375
3,212
3,212
2,886
2,723
2,561
2,561
2,236
2,074
1,912
1,912
1,589
1,427
1,265
1,265
942
780
620
458
4586207809421,2651,2651,4271,5891,9121,9122,0742,2362,5612,5612,7232,8863,2123,2123,3753,5373,86004,0234,1854,50105816020243232323543434144707063727777949962980980010
       Property Plant Equipment 
0
0
0
2
2
1
65
65
60
51
58
58
44
41
43
43
35
32
32
32
24
20
16
16
8
5
1
1
9
8
7
7
7
7
6
6
3
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0000000000002223667777891158161620243232323543434144585851606565122000
       Intangible Assets 
0
0
980
980
960
948
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,500
4,500
4,177
4,015
3,853
3,853
3,530
3,368
3,206
3,206
2,883
2,721
2,559
2,559
2,236
2,074
1,912
1,912
1,589
1,427
1,265
1,265
942
780
619
0
06197809421,2651,2651,4271,5891,9121,9122,0742,2362,5592,5592,7212,8833,2063,2063,3683,5303,8533,8534,0154,1774,5004,5000000000000000000000094896098098000
       Long-term Assets Other 
10
0
0
-2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,697
3,537
3,375
3,212
0
0
0
0
0
0
0
0
0
-2
-2
0
-2
-2
-2
0
457
4570-2-2-20-2-20000000003,2123,3753,5373,697000000000000000000000000000-20010
> Total Liabilities 
0
0
1,420
1,420
2,104
2,395
1,959
1,959
3,090
3,527
4,206
4,206
5,151
4,583
4,739
4,739
5,451
5,991
7,665
7,665
7,353
8,783
8,880
8,881
9,357
13,344
13,564
14,163
13,400
18,793
15,634
15,634
20,369
19,980
23,778
23,778
15,078
15,494
16,981
16,981
19,259
20,355
17,782
17,782
20,755
21,057
33,462
33,462
23,217
23,776
24,746
25,277
25,27724,74623,77623,21733,46233,46221,05720,75517,78217,78220,35519,25916,98116,98115,49415,07823,77823,77819,98020,36915,63415,63418,79313,40014,16313,56413,3449,3578,8818,8808,7837,3537,6657,6655,9915,4514,7394,7394,5835,1514,2064,2063,5273,0901,9591,9592,3952,1041,4201,42000
   > Total Current Liabilities 
0
0
670
670
1,199
1,645
1,753
1,753
2,880
3,329
4,008
4,008
4,961
4,396
4,555
4,555
5,274
5,813
7,483
7,483
6,962
8,289
8,721
8,721
9,202
13,189
13,409
13,409
12,323
17,474
15,479
15,479
20,214
19,825
23,623
23,623
14,923
15,339
16,826
16,826
19,179
20,275
17,702
17,702
20,675
20,977
33,382
33,382
23,137
23,696
24,666
25,197
25,19724,66623,69623,13733,38233,38220,97720,67517,70217,70220,27519,17916,82616,82615,33914,92323,62323,62319,82520,21415,47915,47917,47412,32313,40913,40913,1899,2028,7218,7218,2896,9627,4837,4835,8135,2744,5554,5554,3964,9614,0084,0083,3292,8801,7531,7531,6451,19967067000
       Short-term Debt 
0
0
180
180
415
570
236
236
436
495
715
715
1,350
1,208
1,388
1,388
1,298
1,499
1,519
1,519
1,408
1,559
3,824
2,061
2,380
2,727
4,465
4,735
6,133
7,237
0
6,324
6,782
7,133
0
6,862
6,206
6,101
0
6,634
6,659
6,772
0
7,181
7,357
7,240
0
7,153
7,027
7,057
7,073
7,058
7,0587,0737,0577,0277,15307,2407,3577,18106,7726,6596,63406,1016,2066,86207,1336,7826,32407,2376,1334,7354,4652,7272,3802,0613,8241,5591,4081,5191,5191,4991,2981,3881,3881,2081,35071571549543623623657041518018000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,824
8,413
2,387
2,557
4,465
5,192
5,863
6,967
7,594
6,276
6,782
7,133
6,862
6,180
6,206
6,101
6,634
6,736
6,659
6,772
7,181
7,293
7,357
7,240
7,153
6,900
7,027
7,057
7,073
0
07,0737,0577,0276,9007,1537,2407,3577,2937,1816,7726,6596,7366,6346,1016,2066,1806,8627,1336,7826,2767,5946,9675,8635,1924,4652,5572,3878,4133,8240000000000000000000000
       Accounts payable 
0
0
0
1
0
0
0
1,983
2,444
2,834
3,294
3,750
3,612
3,188
3,167
3,412
3,758
3,809
3,990
4,223
4,379
4,552
4,727
4,686
4,674
3,238
2,714
2,992
3,070
3,180
157
157
281
346
599
599
609
762
701
701
711
753
658
658
786
866
882
884
1,449
1,460
1,080
1,097
1,0971,0801,4601,4498848828667866586587537117017017626095995993462811571573,1803,0702,9922,7143,2384,6744,6864,7274,5524,3794,2233,9903,8093,7583,4123,1673,1883,6123,7503,2942,8342,4441,9830001000
       Other Current Liabilities 
0
0
490
490
784
1,075
1,517
1,517
2,445
2,834
3,294
3,294
3,612
3,188
3,167
3,167
3,976
4,314
5,964
5,964
5,554
6,730
1,934
6,661
6,823
10,462
5,960
8,674
6,190
10,237
4,426
6,752
10,807
8,830
10,600
12,413
3,667
3,457
4,203
4,203
5,904
6,446
3,442
3,442
12,532
12,872
17,362
25,344
5,903
5,903
16,514
17,042
17,04216,5145,9035,90325,34417,36212,87212,5323,4423,4426,4465,9044,2034,2033,4573,66712,41310,6008,83010,8076,7524,42610,2376,1908,6745,96010,4626,8236,6611,9346,7305,5545,9645,9644,3143,9763,1673,1673,1883,6123,2943,2942,8342,4451,5171,5171,07578449049000
   > Long-term Liabilities 
0
0
750
750
905
750
207
207
209
198
197
197
190
187
184
184
178
178
183
183
391
495
0
159
155
155
0
753
1,077
1,320
0
155
155
155
155
155
155
155
155
155
80
80
80
80
80
80
80
80
80
80
80
80
80808080808080808080808015515515515515515515515515501,3201,0777530155155159049539118318317817818418418719019719719820920720775090575075000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
155
155
155
155
155
155
155
155
155
155
155
155
155
155
155
155
155
80
80
80
80
80
80
80
0
0
0
0
0
000008080808080808015515515515515515515515515515515515515515515515515500000000000000000000000
> Total Stockholder Equity
170
100
-430
-430
-1,116
-1,426
-1,881
-1,881
-3,016
-3,463
-4,132
-4,132
-4,955
-4,484
-4,693
-4,693
-5,398
-5,929
-7,589
-7,589
-7,250
-8,519
-8,562
-8,562
-9,154
-13,184
-9,550
-9,550
-9,116
-14,082
-11,392
-11,392
-16,247
-16,566
-20,504
-20,504
-12,183
-12,762
-14,374
-14,374
-16,984
-18,218
-15,774
-15,774
-19,160
-19,606
-32,180
-32,180
-22,202
-22,960
-24,106
-24,801
-24,801-24,106-22,960-22,202-32,180-32,180-19,606-19,160-15,774-15,774-18,218-16,984-14,374-14,374-12,762-12,183-20,504-20,504-16,566-16,247-11,392-11,392-14,082-9,116-9,550-9,550-13,184-9,154-8,562-8,562-8,519-7,250-7,589-7,589-5,929-5,398-4,693-4,693-4,484-4,955-4,132-4,132-3,463-3,016-1,881-1,881-1,426-1,116-430-430100170
   Common Stock
0
0
0
5
5
5
5
5
7
8
8
8
5
8
8
8
10
10
10
10
12
12
13
13
24
28
32
32
36
38
43
43
73
83
0
0
1
2
2
2
6
7
7
7
15
16
21
21
28
28
33
34
343328282121161577762221008373434338363232282413131212101010108885888755555000
   Retained Earnings -68,943-68,234-66,631-65,864-75,119-75,119-61,986-61,383-56,443-56,443-58,840-57,316-53,339-53,339-51,308-50,239-52,935-52,935-47,270-45,864-35,620-35,620-37,002-31,054-29,184-29,184-30,953-24,281-18,374-18,374-17,634-15,416-11,372-11,372-8,532-7,331-6,293-6,293-6,070-6,165-5,333-5,333-4,659-4,207-2,441-2,441-1,851-1,458-440-440-560-490
   Capital Surplus 0000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
660
660
10
10
337
420
554
554
1,184
1,188
1,193
1,193
1,205
1,579
1,592
1,592
1,962
2,635
3,819
3,819
8,208
9,162
-2
9,861
15,173
17,815
-2
19,680
21,981
22,962
-2
24,266
29,626
30,704
-2
32,515
38,142
38,631
-2
38,962
40,326
40,614
-2
40,662
42,209
42,366
-2
42,919
43,636
43,643
44,128
44,143
44,14344,12843,64343,63642,919-242,36642,20940,662-240,61440,32638,962-238,63138,14232,515-230,70429,62624,266-222,96221,98119,680-217,81515,1739,861-29,1628,2083,8193,8192,6351,9621,5921,5921,5791,2051,1931,1931,1881,1845545544203371010660660



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.